title: Aflibercept improves outcome in eyes with poor vision from neovascular age-related macular degeneration.
authors.affiliation: Moorfields Eye Hospital, London, UK.|UCL Institute of Ophthalmology, London, UK.|Royal Surrey County Hospital, Guildford, Surrey, UK.|Bnai Zion Medical Center, Haifa, Israel.
authors.forename: Oren
authors.initials: O
authors.lastname: Tomkins-Netzer
authors.affiliation: Moorfields Eye Hospital, London, UK.|UCL Institute of Ophthalmology, London, UK.
authors.forename: Sophie
authors.initials: S
authors.lastname: Seguin-Greenstein
authors.affiliation: Moorfields Eye Hospital, London, UK.|UCL Institute of Ophthalmology, London, UK.
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Woronkowicz
authors.affiliation: Moorfields Eye Hospital, London, UK.|UCL Institute of Ophthalmology, London, UK.|Royal Surrey County Hospital, Guildford, Surrey, UK.
authors.forename: Sue
authors.initials: S
authors.lastname: Lightman
mesh_terms: D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage* / Q000037:antagonists & inhibitors; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D016896:Treatment Outcome; D014792:Visual Acuity; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor